An American in Paris

These results are incredible and are a testament to several factors: the undaunted and pioneering work of rheumatology investigators; the remarkable development of targeted therapies by industry; and an unparalleled cooperation of clinical investigators, in academics and industry, throughout the world.

These accomplishments have produced striking benefits. The lives of patients with RA have been transformed and there is much to inspire both gratitude and pride.

Ce n’est pas la même chose.

In my next column, I will discuss the powerful implications of that statement for rheumatology today.

Dr. Pisetsky is physician editor of The Rheumatologist and professor of medicine and immunology at Duke University Medical Center in Durham, N.C.

Differences in its epidemiologic, clinical and immunologic features underscore need for a homogeneous diagnostic and therapeutic approach

Strategies to identify and track remission in your RA patients

Over the past few years, the ARHP and the European League Against Rheumatism (EULAR) health professional (HP) leaders have met informally at the EULAR Congress and the ACR/ARHP Annual Meeting to identify a mutually beneficial project to be pursued. At the 2013 EULAR Congress, ARHP and EULAR leaders agreed to formally organize a meeting of…

The impressive progress of medical knowledge and technology reinforces our trust in the scientific methodology that made it all possible. However, that progress also creates risks related to the primary goal of medical care: to serve our patients’ interests and enjoyment of life in the best possible way. In this article we present our views…

Systemic Sjögrens: More Than a Sicca Disease

Target Remission

ARHP/EULAR Health Professionals Collaboration Update

The Dual-Target Strategy in Rheumatoid Arthritis: Put Patients First

Related Articles